According to Revelation Biosciences, the company has received clearance from an ethics committee for an Australian Phase 1b allergen challenge study of its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD) for the treatment of allergic rhinitis and chronic nasal congestion. The trial, called RVL-CLR01, is expected to begin in the fourth quarter of 2021 and will enroll up to 28 subjects. Topline data are expected in the first quarter of 2021.
The company, which has been developing the nasal drops for the treatment of viral respiratory infections, announced the initiation of a Phase 1a trial in November 2020. In early 2021, Revelation announced that it intended to use some of the funds raised in a private placement for additional indications for REVTx-99.
Revelation Biosciences CEO James Rolke said, “REVTx-99 is being developed for preventing and treating respiratory viral infections, like influenza and COVID-19. However, based on our Phase 1 biomarker data, we believe REVTx-99 may also prove successful in reducing allergy symptoms, including chronic nasal congestion.”
Read the Revelation Biosciences press release.
